DE69623595T2 - Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen - Google Patents

Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen

Info

Publication number
DE69623595T2
DE69623595T2 DE69623595T DE69623595T DE69623595T2 DE 69623595 T2 DE69623595 T2 DE 69623595T2 DE 69623595 T DE69623595 T DE 69623595T DE 69623595 T DE69623595 T DE 69623595T DE 69623595 T2 DE69623595 T2 DE 69623595T2
Authority
DE
Germany
Prior art keywords
topical administration
hyperproliferative epithelial
treating hyperproliferative
crosslinking compounds
epithelial lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623595T
Other languages
English (en)
Other versions
DE69623595D1 (de
Inventor
Caroline Stanwell
Stuart H Yuspa
Burke, Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69623595D1 publication Critical patent/DE69623595D1/de
Publication of DE69623595T2 publication Critical patent/DE69623595T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69623595T 1995-02-17 1996-02-14 Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen Expired - Lifetime DE69623595T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/389,845 US5610185A (en) 1995-02-17 1995-02-17 Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds
PCT/US1996/002301 WO1996025159A1 (en) 1995-02-17 1996-02-14 A method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds

Publications (2)

Publication Number Publication Date
DE69623595D1 DE69623595D1 (de) 2002-10-17
DE69623595T2 true DE69623595T2 (de) 2003-05-22

Family

ID=23539975

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623595T Expired - Lifetime DE69623595T2 (de) 1995-02-17 1996-02-14 Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen

Country Status (11)

Country Link
US (1) US5610185A (de)
EP (1) EP0809493B1 (de)
JP (1) JPH11503111A (de)
AT (1) ATE223715T1 (de)
AU (1) AU698414B2 (de)
CA (1) CA2212888C (de)
DE (1) DE69623595T2 (de)
DK (1) DK0809493T3 (de)
ES (1) ES2183938T3 (de)
PT (1) PT809493E (de)
WO (1) WO1996025159A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
FR2778560B1 (fr) 1998-05-12 2001-06-01 Oreal Utilisation de l'acide cinnamique ou d'au moins l'un de ses derives dans une composition destinee a favoriser la desquamation de la peau, et composition le comprenant
GB2370989A (en) * 2001-01-16 2002-07-17 Btg Int Ltd Piperine analogues for the treatment of skin conditions
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
US7368593B1 (en) 2003-08-18 2008-05-06 Organics L.L.C. Method of selective esterification
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
WO2005092322A1 (ja) * 2004-03-29 2005-10-06 Japan Health Sciences Foundation Ｒａｒ活性化を起こす天然化合物
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
FR2892923B1 (fr) * 2005-11-08 2009-01-16 Engelhard Lyon Sa Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
US8541467B2 (en) 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
US20080114075A1 (en) 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492815A1 (fr) * 1980-10-23 1982-04-30 Sori Soc Rech Ind Nouveau derive d'acide cinnamoyl-cinnamique, son procede de preparation et son application en therapeutique
US4925877A (en) * 1986-02-25 1990-05-15 Zaidanhojin Biseibutsu Kagaku Kenkyukai Physiologically active erbstatin analogue compounds and compositions
FR2601670B1 (fr) * 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
JPH03109323A (ja) * 1989-09-22 1991-05-09 Microbial Chem Res Found 抗ガン剤
US5360815A (en) * 1993-06-23 1994-11-01 Merck Frosst Canada, Inc. Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
JPH0761919A (ja) * 1993-08-26 1995-03-07 Kao Corp 美白剤

Also Published As

Publication number Publication date
CA2212888A1 (en) 1996-08-22
EP0809493B1 (de) 2002-09-11
EP0809493A1 (de) 1997-12-03
ES2183938T3 (es) 2003-04-01
DE69623595D1 (de) 2002-10-17
PT809493E (pt) 2003-01-31
AU698414B2 (en) 1998-10-29
CA2212888C (en) 2006-10-17
DK0809493T3 (da) 2002-12-23
JPH11503111A (ja) 1999-03-23
ATE223715T1 (de) 2002-09-15
US5610185A (en) 1997-03-11
WO1996025159A1 (en) 1996-08-22
AU4928696A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
DE69623595T2 (de) Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen
DE69622265D1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
MX9707665A (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
DE69433079D1 (de) Verwendung von imidazole zur behandlung von krankheiten, die durch neovaskularisierung gekennzeichnet sind
DE69739734D1 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
ES2194987T3 (es) Compuestos triciclicos utiles para inhibir la farnesil-protein-transferasa.
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
ZA947969B (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
DE69317578T2 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69625906D1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE69706566D1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
DE69329559D1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69328635D1 (de) Verwendung eines stoffgemisches enthaltend alpha hydroxy organische säure zur herstellung eines arzneimittels zur behandlung von kleinen mundgeschwüren
CA2267165A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
DE69330465D1 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
DE69623767T2 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69717844T2 (de) Neue cis-3,4-chromanderivate zur vorbeugung oder behandlung von oestrogenbezogenen krankheiten oder syndromen
DE69400702D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
NZ320522A (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds
DE69715227D1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit
CA2239520A1 (en) Use of 1-hydroxy-2-pyridones for treating mucosal disorders which are difficult to treat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition